Major depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing to treatment-resistant depression (TRD).

IntroductionMajor depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing ...

FDA's rejection of MDMA therapy for PTSD doesn't dampen hopes for other psychedelic treatments. Read more here.

Languages: English That has some policy experts confused about the FDA's ability to implement efficient recalls and protect Americans from foodborne illness or public health hazards. More ...

The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical company Johnson & Johnson created the spray from esketamine, a more ...

But it remains costly — and controversial Health Canada approved a prescription esketamine nasal spray called Spravato in 2020 to help with treatment-resistant depression. Brandi Martin ...

Esketamine, a molecular relative of regular ketamine, was approved as a TRD treatment in 2019, but until now, it had to be taken alongside a second, traditional antidepressant. Now, the new FDA ...

Copyright 2025 The Associated Press. All Rights Reserved. Two pedestrians walk on the campus of Tufts University, Friday Jan. 31, 2025 in Medford, Mass., where an ...

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

Jan. 31, 2025 – The FDA has approved a new non-opioid oral drug for acute pain in adults. It is the first new class of non-opioid pain medicine approved in over 20 years, providing effective ...